Please login to the form below
Biosimilars - the Brexit of the pharmaceutical industry?
In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities of Britain exiting the EU (Brexit).
Despite
availability of biosimilars for nearly a decade, uptake in the UK is still
lagging behind other EU markets, leading to the recent formation of the British Biosimilars Association (BBA) - part of the British Generic Manufacturers Association (BGMA).
Biosimilars
are undoubtedly a hot topic for providers of branded biologic medicines,
biosimilar suppliers themselves, and the payers, healthcare professionals and
patients involved in biologic treatment. Much like the EU referendum, they
feature regularly in the news - with spectators waiting anxiously, in some
cases eagerly, for a change that could alter the treatment landscape for
several significant therapy areas.
To
understand the factors influencing the uptake of biosimilars you could apply
the same principles as you would to navigating the complexities of Britain
exiting the EU (Brexit).
Read the full article on the Blue Latitude Health blog
1. Control is in the hands of the people
Britain's relationship with the EU will be decided by a referendum, placing the decision in the hands of the people. In the UK, the decision to prescribe a biosimilar is still largely down to the healthcare professional (HCP) but, if this were to change, impact on biologic markets could be dramatic. Despite NICE recommending biosimilars ahead of branded biologics in several disease areas, this does not appear to be happening in clinical practice. The next step for governing bodies to ensure biosimilars are prioritised in the treatment pathway is substitution, replacing a branded biologic with its corresponding biosimilar at point of dispensing; a move that would result in a huge uplift in biosimilar use. Arguably, the reason this hasn’t happened yet is that the financial gain generated by such a move does not yet outweigh the repercussions of reducing the role of the HCP in such an important decision. But with increasing pressure on the NHS to make cost savings and expect greater value from treatments, this could change in the future.Read the full article on the Blue Latitude Health blog
Company Details
Blue Latitude Health
+44 203 328 1840
Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom
Latest content on this profile
- Digital Nation: How Australia became a digital health pioneer
- Australia has adopted digital strategies to transform its healthcare system. We sat down with Rachel de Sain, who shares where, and how she contributed to improving digital health products and services in Australia to advance their nation to becoming one of the world's leaders in digital health.
Blue Latitude Health
- Rethinking Electronic Medical Records
- EMR systems are far from perfect. Clinician and PhD candidate Dr. Pao takes us through his perspective on the system and how he aims to lead the way by solving the challenges when adopting this technology in a clinical setting.
Blue Latitude Health
- Blue Latitude Health moves to new offices in New York
- Blue Latitude Health has moved offices to a new location in New York following a year of substantial growth.
Blue Latitude Health
- Designing a global digital patient services platform
- Within our customer experience capability at Blue Latitude Health, our UX researchers and designers are tasked with understanding customer and client needs. Recently, a client required a centralised system to drive the development and deployment of data-driven patient services. Here, we explain the process of developing this platform.
Blue Latitude Health
- Digital therapeutics and their impact on society
- Head of Customer Experience Elisa del Galdo explores how healthcare technology can help chronic disease patients and asks what makes a good digital therapeutic?
Blue Latitude Health
- Life with multiple myeloma - why I'm a lucky man living the dream
- Multiple myeloma patient Bob Munro explains what it's like to live with the rare blood cancer and how his diagnosis led him on the journey of a lifetime – cycling from London to the Arc de Triomphe.
Blue Latitude Health
